BLRD Research Career Scientist Award Application

这项建议旨在延长由Shyam S Mohapatra博士在 自2007年起在佛罗里达州坦帕市的詹姆斯·A·黑利退伍军人医院工作。他是一位杰出的健康人士 转化医学研究中心教授兼主任 退伍军人事务部附属学术中心--南方大学的纳米生物工程教育 佛罗里达。他在纳米领域的贡献在国内和国际上都得到了认可 与许多炎症性疾病有关的生物医学诊断和治疗，包括 哮喘、病毒感染、创伤性脑损伤和癌症。他收到了大量的 校外研究支持，包括来自NIH，DOA，ONR，退伍军人事务部的奖项 事务和佛罗里达州卫生部。除了在他早期的两个国际奖项之外 学术生涯，他是USF生物技术奖、Sigma XI奖、TBTF的获奖者 技术领先奖、卓越研究与创新奖和全球 纳米技术公司奖。他对科学文献做出了重大贡献 包括170多篇出版物，其中一些发表在非常有影响力的期刊上，如《自然医学》和 临床调查杂志，并拥有30项美国和外国专利。他是世界上最大的 美国国家发明家学会和美国医学与生物研究所 工程学。为了表彰他对生物医学纳米技术的贡献，他被选为 2014年荣登“佛罗里达发明家名人堂”。此外，他还将自己的努力投入到训练中 临床研究员和研究生在退伍军人医院从事研究和教学。 莫哈帕特拉博士自1996年以来一直是退伍军人医院的研究调查员， 获得了专注于呼吸道合胞病毒(RSV)感染的功绩审查奖的资助 从1999年开始。他的实验室为新的基因组方法的翻译做出了重大贡献 例如涉及小干扰RNA(SiRNA)和microRNA的那些以及新兴的 纳米医学，前提是这些技术将有助于开发新的治疗方法 困扰退伍军人的疾病的诊断和治疗。当前需要支持的研究活动 本次RCS奖获得者名单如下。 项目1.利用新的纳米尺度开发新的预防和/或治疗方法 对原发和继发呼吸道合胞病毒感染有效的技术，广泛 适用于所有年龄段，价格低廉。他提议的绩效审查项目(A1修订本为 提交)旨在开发一种简单、智能和可扩展的纳米胶束系统，该系统结合了 病毒融合、细胞抗病毒和复制抑制药的靶标。 项目2：在大鼠身上研究一种新的联合治疗方法的潜力 中度创伤性脑损伤模型，包括(I)治疗以减少炎症(局部和全身)，使用 针对新近发现的靶CCL20的纳米配方siRNA，以及(Ii)第二种治疗 通过间充质干细胞治疗促进神经再生。 项目3.开发一种新的基于细胞学的个性化癌症治疗方法 一个四维(4D)类肿瘤培养平台。这种化验方法可以单独使用，也可以作为辅助手段。 目前正在进行的基因组检测，预测药物(S)将是最多的 适用于那个病人的癌症的治疗。 纳米医学方法的这些创新应用结合在一起有望 为退伍军人和其他有需要的美国人带来高效果的治疗。好了！

This proposal seeks to renew Research Career Scientist Award held by Dr. Shyam S Mohapatra at the James A. Haley VA Hospital in Tampa, Florida since 2007. He is a Distinguished Health Professor and the Director of the Division of Translational Medicine- Center for Research and Education in Nanobioengineering at the VA-affiliated academic center- the University of South Florida. He is recognized nationally and internationally for his contribution to the field of nanoscale biomedical diagnostics and therapeutics in relation to a number inflammatory diseases including asthma, viral infections, traumatic brain injury (TBI) and cancers. He has received substantial extramural research support including awards from the NIH, DOA, ONR, Department of Veterans’ Affairs and Florida Department of Health. In addition to the two international awards early in his academic career, he is the recipient of the USF biotechnology award, the Sigma XI award, TBTF Technology Leadership Award, Excellence in Research and Innovation award and Global Corporate award in Nanotechnology. He has contributed substantially to scientific literature including over 170 publications, some in very high impact journals such as Nature Medicine and journal of Clinical Investigation, and has >30 U.S. and foreign patents. He is a Fellow of the National Academy of Inventors and of the American Institute of Medical and Biological Engineering. In recognition of his contribution to the biomedical nanotechnology, he was inducted to the “Florida Inventors’ Hall of Fame” in 2014. In addition, he has devoted his efforts in training clinical fellows and graduate students in research and teaching at the VA hospital. Dr. Mohapatra has been a research investigator at the VA Hospital since 1996 and has been funded with the Merit Review Award focused on respiratory syncytial virus (RSV) infection since 1999. His lab has contributed substantially to the translation of new genomic approaches such as those involving small-interfering RNAs (siRNA) and microRNAS and emerging field of nanomedicine, with the premise that these technologies will aid in developing new methods for diagnosis and therapy of diseases afflicting Veterans. Current research activities to be supported by this RCS Award are as follows. Project #1. Develop new prophylactic and/or therapeutic approaches using novel nanoscale technologies, which are effective against both primary and secondary RSV infections, broadly useful in all age groups and inexpensive. His proposed merit review project (A1 revision to be submitted) aims to develop a simple, smart and scalable nanomicellar system that combines novel targets for viral fusion-, cellular antiviral- and replication-inhibitors. Project #2. Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell therapy. Project #3. Develop a novel cellomic-based personalized cancer treatment approach using a four-dimensional (4D) tumoroid culture platform. The assay can be used by itself or as an adjunct assay to currently practiced genomic testing, which predicts drug(s) that will be the most appropriate for the treatment of that patient’s cancer. These innovative applications of nanomedicine approaches taken together are expected to lead to high impact therapies for Veterans and other Americans in need. !